Agendia partners with the West German Study Group to determine the benefit of ovarian function suppression, potentially reducing overtreatment with chemotherapy Trial reinforces Agendia's
WSG and CANKADO's EnReP predicts the benefits of anti-hormone openpr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from openpr.com Daily Mail and Mail on Sunday newspapers.
The tool developed on the basis of the ADAPT study data will be presented today at SABCS 2020
Cologne, Germany, 11.12.2020 – The EnReP (Endocrine Response Predictor) assessment tool will be presented today at the San Antonio Breast Cancer Symposium SABCS 2020. EnReP is a tool developed in Germany that can be used to predict the probability of response to endocrine therapy in early-stage breast cancer patients. Endocrine therapy is the standard therapy for hormone receptor-positive (HR+) / HER2-negative (HER2-) breast cancer patients.
The ADAPT study program evaluates options for patient-specific decision-making for breast cancer treatment based on modern biological markers. A central component here is the examination of the tumor’s response to a brief anti-hormone therapy prior to operation.